Treating the Endothelium to Restore Insulin Sensitivity

NCT ID: NCT00402194

Last Updated: 2013-09-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 17 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-06-30
• Study Completion Date: 2012-03-31

Brief Summary

A study of 12 weeks' treatment with losartan or placebo, to test the hypothesis that RAS inhibition will improve insulin' vascular actions and therefore improve insulin sensitivity in skeletal muscle.

Detailed Description

Recent studies suggesting an effect of cardiovascular therapies to prevent diabetes remain unexplained. We hypothesize that these therapies improve vascular endothelial function allowing improved actions of insulin in the vasculature, which comprise a significant portion of insulin's metabolic action. We therefore propose to measure insulin-mediated glucose disposal and insulin-mediated vasodilation before and after 12 weeks' therapy with Losartan (an angiotensin receptor blocker) or placebo, in a randomized design. Subjects will include 28 subjects with impaired glucose tolerance, which is generally accompanied by both insulin resistance and impaired vascular function. With this number of participants we have a 90% chance of showing a statistically significant and clinically meaningful effect of insulin on leg vascular resistance, and an even higher chance of showing a difference in insulin's metabolic effects. Exclusion criteria will include frank hypertension, diabetes, or hypercholesterolemia, and biochemical or other contraindications to losartan therapy. The primary endpoint for statistical analysis will be the invasive measure of insulin-stimulated endothelial function. We anticipate an improvement in both vascular and metabolic measures of insulin action following Losartan therapy but no change from untreated baseline following placebo.

Conditions

Obesity; Insulin Resistance; Impaired Glucose Tolerance; Pre-diabetes

Study Design

• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Interventions

Losartan

Tablet, 100mg, once per day for 3 months

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy
• Age 20-55
• Male and female
• Obese, defined as Males: BMI >28 or > 30% fat by DEXA scan or Bod Pod; Females: BMI >30 or > 33% fat by DEXA scan or Bod Pod
• Weight stable over at least 4 months

Exclusion Criteria

• Diabetes mellitus (ADA criteria)
• Age <20 or > 55 yrs
• Blood pressure >160/90 or < 90/65 mmHg
• Total cholesterol >240 or LDL cholesterol >160 mg/dL
• Baseline elevations in AST or ALT > 3X ULN
• Baseline elevation in creatinine >1.6 ng/mL
• Unexplained baseline elevation in creatine kinase > 3X ULN
• Concurrent significant chronic medical illness including, but not limited to, human immunodeficiency virus infection, Syphilis, hepatitis B infection, or hepatitis C infection
• Pregnancy
• Known hypersensitivity or intolerance to the study agents

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Indiana University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kieren J Mather, MD

Role: PRINCIPAL_INVESTIGATOR

Indiana University

Locations

Indiana University Hospital GCRC

Indianapolis, Indiana, United States

Countries

United States

Other Identifiers

IU-IRB-0301-08

Identifier Type: -

Identifier Source: org_study_id